124782-95-2

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE is used as a pharmacological agent for its potential antimalarial and antitumor properties, serving as a foundation for the development of new treatments in these therapeutic areas.
Used in Medicinal Chemistry Research:
6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE is used as a research compound to explore its chemical and biological properties, contributing to the advancement of knowledge in medicinal chemistry.
Used in Drug Development:
6-BROMO-2-PIPERAZIN-1-YL-QUINOLINE is used as a synthetic intermediate in the creation of various pharmaceutical compounds, facilitating the design and synthesis of new drugs with potential therapeutic benefits.

InChI:InChI=1/C13H14BrN3/c14-11-2-3-12-10(9-11)1-4-13(16-12)17-7-5-15-6-8-17/h1-4,9,15H,5-8H2

Upstream product

• 1637483-39-6 tert-butyl 4-(6-bromoquinolin-2-yl)piperazine-1-carboxylate 
• 3279-90-1 6-bromo-3,4-dihydro-1H-quinolin-2-one 
• 1810-71-5 6-bromo-2-chloroquinoline 
• 553-03-7 3,4-dihydro-2(1H)-quinolone 

Relevant academic research and scientific papers

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS

Compounds of the formula I: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1

6-Nitroquipazine has been known as one of the most potent and selective inhibitors of serotonin transporter in vitro and in vivo. Nine derivatives of 6-nitroquipazine were synthesized and tested for their potential abilities to displace [3H]citalopram binding to the rat cortical membranes. (C) 2000 Elsevier Science Ltd. All rights reserved.